Download Full Text (1.0 MB)
- Estimate the proportion of patients who achieve a plasma apixaban concentration of/mL following at least 48 hours of discontinuation prior to surgery or invasive procedure
- Perioperative and follow up arterial or venous thromboembolic events, major bleeding, clinically significant non-major bleeding complications. Correlation of apixaban anti-Factor Xa (FXa) activity and plasma apixaban concentrations at pre-admission and prior to surgery
perioperative anticoagulation, direct acting oral anticoagulant, bleeding
Medical Pharmacology | Medicine and Health Sciences | Surgery
Lam, Edwin; Eraso, Luis; Galanis, Taki; Kraft, Walter K.; Ouma, Geoffrey; Thomson, Lynda; Viscusi, Eugene; Stickle, Douglas; Gong, Jerald Z.; Adams, Suzanne; and Merli, Geno, "Apixaban Discontinuation Prior To Major Surgery: Results From A Prospective Single Center Study" (2019). Department of Pharmacology and Experimental Therapeutics Posters. 6.